An observational study in Kidney Disease, Kidney Injury and Transgender Individuals, sponsored by Amsterdam UMC, location VUmc. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Amsterdam UMC, location VUmc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Kidney Diseases with a site in Netherlands — 6 open to participants now, 10 under way, 5 of them phase 3. Kidney Diseases · Netherlands.
Among the 36 studies in Kidney Diseases with a site in Netherlands, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 35th registered.
970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.
Browse Kidney Diseases studies →6 of the 36 studies in Kidney Diseases with a site in Netherlands are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Netherlands
Ages 25–55 · Healthy volunteers
Eli Lilly and Company · Sites in Netherlands, Argentina, Australia and 35 more countries
Ages 50+
University Medical Center Groningen · Sites in Netherlands
Healthy volunteers
Takeda · Sites in Netherlands, United States, Argentina and 23 more countries
Ages 18+
eleva GmbH · Sites in Netherlands, Austria, Belgium and 9 more countries
Ages 18+ · Healthy volunteers
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 13 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 246 across 278 observational studies indexed under Kidney Diseases.
Median enrollment 150 across the 31 interventional studies, 93 across the 5 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 36 have an industry lead sponsor. The 10 most frequent:
Amsterdam UMC, location VUmc is the lead sponsor of 305 studies on the registry; 84 are open to participants now.
Amsterdam UMC, location VUmc has 1 study filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Kidney Diseases with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT07483827eleva GmbHA Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy | 2026-11 |
| NCT07600450GlaxoSmithKlineA Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive | 2027-05-20 |
| NCT06734234GlaxoSmithKlineA Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease | 2027-07-23 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Kidney Diseases with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates how sex hormones affect kidney function in people undergoing gender-affirming hormone therapy (GAHT). We know men have a faster progression of kidney disease. Earlier studies suggest that the female sex hormone estradiol may have a protective effect on kidney function while the male sex hormone testosterone may have the opposite effect. But the reasons why this happens remain unclear. By studying participants undergoing (GAHT) we gain insight into the mechanisms by which testosterone and estradiol influence the kidneys. People undergoing GAHT provide a unique chance to study how sex hormones interact with the kidneys. The results may help us to understand why men and women exhibit differences in kidney disease development. This study will include 30 men and 30 women, aged 18 to 40, who start GAHT. Participants will have three study visits, two of which will happen during their scheduled healthcare appointments. During the first visit, a screening will take place to check if patients can take part in the study. At study visits before and after one year of therapy, kidney function is measured, kidney MRI is performed, urine is collected and a small sample of fat tissue. Taking part in the study does not delay the start of GAHT.
Sex differences in kidney physiology are a vastly understudied area, despite known differences in sex-specific rates of chronic kidney disease. Kidney function decline is accelerated in men compared to women, suggesting a potential harmful role for testosterone. Transgender individuals undergoing hormone therapy provide a unique model to study the effects of gender affirming hormone therapy on kidney function and renal physiology. The central objectives of this study are to comprehensively assess the effects of gender affirming hormone therapy (GAHT; testosterone in transgender men or estradiol and an anti-androgen in transgender women) therapy on kidney function and physiology. This study is a prospective observational study. In total we will include 60 transgender individuals (30 transgender men and 30 transgender women) between 18-40 years old, scheduled to start GAHT. The primary endpoint is measured glomerular filtration rate (GFR) by iohexol clearance. Secondary endpoints include effects of GAHT on measures of intrarenal hemodynamic function including effective renal plasma flow (ERPF), proximal tubular function, insulin sensitivity and multiparametric kidney MRI (phase-contrast MRI [perfusion], arterial spin labeling [perfusion], BOLD imaging with a multi-echo spin-echo mapping R2* [oxygenation] and diffusion-weighted MRI [diffusion]). We will also isolate urinary tubuloids to further study the effect of sex hormones on kidney physiology and in these tubuloids we will assess whether the kidney protective effects are affected by sex hormones in vitro. Furthermore, endothelial cells will be harvested by J-wire, and single-cell RNA sequencing will be performed to investigate the transcriptional effects of GAHT in endothelial cells. And finally, we will look at adipose tissue gene expression.The burden for participants consists of three study visits, two of which will replace scheduled meetings that are a part of standard healthcare practice. In total, participants will receive one venipuncture and four intravenous cannulas, from which blood will be sampled (study total of 275 mL) and iohexol and p-aminohippurate will be administered to measure GFR and ERPF respectively. After measurement of kidney function, insulin sensitivity will be measured using a variable infusion of glucose and insulin (hyperinsulinemic euglycemic clamp). Patients will undergo kidney MRI which will take about 45 minutes; participants with claustrophobia are excluded. In addition, participants will be asked to collect a 24-hour urine sample on the days prior to the second and third study visit. Subcutaneous adipose tissue is collected by needle aspiration after local anesthesia. Finally, endothelial cells will be harvested. The total risk of negative effects for participants in the current study is considered low. The transgender population is a unique population in which the effects of exogenous cross-sex hormone administration can be studied. This study may provide additional data on the safety of hormone therapy in this population and may also lead to meaningful insights regarding the physiological effects of sex hormones on kidney function in humans that may help to understand observations from cohort studies which indicate differences in progression to kidney failure dependent on gender.
The source population consists of adult patients with gender dysphoria, who are scheduled to start with GAHT in the Amsterdam University Medical Centre (AUMC) in Amsterdam. A total of 60 transgender individuals (30 transgender women, 30 transgender men) will be selected from this outpatient clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals clinically scheduled to start GAHT with testosterone therapy
Diagnostic Test: P-aminohippurate clearance study · Diagnostic Test: Iohexol infusion · Diagnostic Test: Hyperinsulinemic clamp
Individuals clinically scheduled to start GAHT with estradiol and anti-androgen therapy
Diagnostic Test: P-aminohippurate clearance study · Diagnostic Test: Iohexol infusion · Diagnostic Test: Hyperinsulinemic clamp
To measure effective renal plasma flow (ERPF), small doses of a substance called p-aminohippurate will be used
To measure glomerular filtration rate (GFR) iohexol clearance will be performed
Glucose/insulin infusion to measure insulin sensitivity
Change in measured glomerular filtration rate (GFR)
Time frame: Baseline, 12 months after start GAHT
Change in effective renal plasma flow (ERPF)
Time frame: Baseline, 12 months after start GAHT
Change in systemic hemodynamic function
Time frame: Baseline, 12 months after start GAHT
Change in insulin sensitivity
Time frame: Baseline, 12 months after start GAHT
Change in markers of tubular physiology
Time frame: Baseline, 12 months after start GAHT
Changes in multiparametric kidney MRI
Including (phase-contrast MRI (perfusion), arterial spin labeling (perfusion), BOLD imaging with multi-echo spin-echo mapping R2\* (oxygenation) and diffusion-weighted (DW) MRI (diffusion)
Time frame: Baseline, 12 months after start GAHT
Changes in endothelial function
Time frame: Baseline, 12 months after start GAHT
Change in adipose tissue gene expression and adipose tissue biology
Time frame: Baseline, 12 months after start GAHT
Change in tubular effects of kidney protective therapies in vitro
Time frame: Baseline, 12 months after start GAHT
Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.
Of 100 non-industry observational studies under Kidney Diseases, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 33. This study's planned 24 months is below that.
Counting every sponsor, half of 117 studies reached it within 59 months; a quarter within 31 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amsterdam UMC, location VUmc →